Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
Not Applicable
- Conditions
- Myocardial Infarction
- Interventions
- Procedure: administration of tirofiban by guide catheterProcedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
- Registration Number
- NCT01181388
- Lead Sponsor
- Beijing Anzhen Hospital
- Brief Summary
Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- STEMI patients
- chest pain for less than 12hr
- plan to PCI
Exclusion Criteria
- LM lesion
- stent thrombosis
- cardiac shock
- thrombocytopenia
- allergy to asprin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description intra-guide-catheter infusion of tirofiban administration of tirofiban by guide catheter - intra-thrombus-aspiration-catheter infusion of tirofiban administration of tirofiban by thrombus aspiration catheter in infarct-related artery -
- Primary Outcome Measures
Name Time Method Major adverse cardiovascular events 3 months after PCI Infarct size, reinfarction, motality, et.al.
Major Adverse Cardiovascular Events 6 months after PCI Infarct size, reinfarction, motality, et.al.
- Secondary Outcome Measures
Name Time Method number of participants with bleeding events 1 month bleeding events are assessed by Thrombolysis In Myocardial Infarction(TIMI) criteria
Trial Locations
- Locations (1)
the 28th division, Beijing Anzhen Hospital
🇨🇳Beijing, Beijing, China